BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang Y, Han QJ, Zhang J. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World J Gastroenterol 2019; 25(25): 3151-3167 [PMID: 31333308 DOI: 10.3748/wjg.v25.i25.3151] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Ceausu M, Socea B, Serban D, Smarandache CG, Predescu D, Bacalbaşa N, Slavu I, Tulin A, Alecu L, Ceauşu Z. Heterogeneity of antigenic constellation in human hepatocellular carcinoma. Exp Ther Med 2021;21:270. [PMID: 33603877 DOI: 10.3892/etm.2021.9701] [Reference Citation Analysis]
2 Wang W, Pan F, Lin X, Yuan J, Tao C, Wang R. Ferroptosis-Related Hub Genes in Hepatocellular Carcinoma: Prognostic Signature, Immune-Related, and Drug Resistance Analysis. Front Genet 2022;13:907331. [DOI: 10.3389/fgene.2022.907331] [Reference Citation Analysis]
3 Wang X, Zhang X. Hepatocellular adenoma: Where are we now? World J Gastroenterol 2022; 28(14): 1384-1393 [DOI: 10.3748/wjg.v28.i14.1384] [Reference Citation Analysis]
4 Krishnan MS, Rajan Kd A, Park J, Arjunan V, Garcia Marques FJ, Bermudez A, Girvan OA, Hoang NS, Yin J, Nguyen MH, Kothary N, Pitteri S, Felsher DW, Dhanasekaran R. Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers. Hepatology 2021;73:2342-60. [PMID: 33140851 DOI: 10.1002/hep.31614] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
5 Xu H, Xiong C, Chen Y, Zhang C, Bai D. Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma. Bioengineered 2021;12:2664-75. [PMID: 34115569 DOI: 10.1080/21655979.2021.1938470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Azbazdar Y, Karabicici M, Erdal E, Ozhan G. Regulation of Wnt Signaling Pathways at the Plasma Membrane and Their Misregulation in Cancer. Front Cell Dev Biol 2021;9:631623. [PMID: 33585487 DOI: 10.3389/fcell.2021.631623] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
7 Dai Y, Qiang W, Lin K, Gui Y, Lan X, Wang D. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma. Cancer Immunol Immunother 2021;70:967-79. [PMID: 33089373 DOI: 10.1007/s00262-020-02743-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Zhang B, Tang B, Lv J, Gao J, Qin L. Systematic analyses to explore immune gene sets-based signature in hepatocellular carcinoma, in which IGF2BP3 contributes to tumor progression. Clin Immunol 2022;241:109073. [PMID: 35817291 DOI: 10.1016/j.clim.2022.109073] [Reference Citation Analysis]
9 Hong R, Gu J, Niu G, Hu Z, Zhang X, Song T, Han S, Hong L, Ke C. PRELP has prognostic value and regulates cell proliferation and migration in hepatocellular carcinoma. J Cancer 2020;11:6376-89. [PMID: 33033521 DOI: 10.7150/jca.46309] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Zhao Y, Xue C, Xie Z, Ouyang X, Li L. Comprehensive analysis of ubiquitin-specific protease 1 reveals its importance in hepatocellular carcinoma. Cell Prolif 2020;53:e12908. [PMID: 32951278 DOI: 10.1111/cpr.12908] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zeng Z, Yang B, Liao ZY. Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma. Oncol Lett 2020;20:45. [PMID: 32802167 DOI: 10.3892/ol.2020.11909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
12 Opo FADM, Rahman MM, Ahammad F, Ahmed I, Bhuiyan MA, Asiri AM. Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identification of natural anti-cancer agents targeting XIAP protein. Sci Rep 2021;11:4049. [PMID: 33603068 DOI: 10.1038/s41598-021-83626-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
13 Wu P, Shi J, Sun W, Zhang H. The prognostic value of plasma complement factor B (CFB) in thyroid carcinoma. Bioengineered 2021;12:12854-66. [PMID: 34898340 DOI: 10.1080/21655979.2021.2005745] [Reference Citation Analysis]
14 Leone P, Solimando AG, Fasano R, Argentiero A, Malerba E, Buonavoglia A, Lupo LG, De Re V, Silvestris N, Racanelli V. The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. Vaccines (Basel) 2021;9:532. [PMID: 34065489 DOI: 10.3390/vaccines9050532] [Reference Citation Analysis]
15 Dong W, Xie Y, Huang H. Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma. Front Endocrinol 2022;13:884777. [DOI: 10.3389/fendo.2022.884777] [Reference Citation Analysis]
16 Wang Y, Yang Y, Zhao Z, Sun H, Luo D, Huttad L, Zhang B, Han B. A new nomogram model for prognosis of hepatocellular carcinoma based on novel gene signature that regulates cross-talk between immune and tumor cells. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09465-9] [Reference Citation Analysis]
17 Wang J, Li R, Huang C, Hong C, Li Q, Zeng L, He J, Hu C, Cui H, Liu L, Xiao L. Impact of antibiotics on the efficacy of immune checkpoint inhibitors in the treatment of primary liver cancer☆. Liver Research 2022. [DOI: 10.1016/j.livres.2022.05.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Liu C, Pan J, Liu H, Lin R, Chen Y, Zhang C. Daphnetin inhibits the survival of hepatocellular carcinoma cells through regulating Wnt/β-catenin signaling pathway. Drug Dev Res 2022. [PMID: 35132666 DOI: 10.1002/ddr.21920] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sun L, Mu L, Zhou J, Tang W, Zhang L, Xie S, Chen J, Wang J. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunol Immunother 2021. [PMID: 33993366 DOI: 10.1007/s00262-021-02957-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Cao L, Zhu YQ, Wu ZX, Wang GX, Cheng HW. Engineering nanotheranostic strategies for liver cancer. World J Gastrointest Oncol 2021; 13(10): 1213-1228 [PMID: 34721763 DOI: 10.4251/wjgo.v13.i10.1213] [Reference Citation Analysis]
21 Liu X, Ren H, Guo H, Wang W, Zhao N. Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma. Clin Exp Immunol 2021;203:219-29. [PMID: 33030251 DOI: 10.1111/cei.13535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Khedr OMS, El-Sonbaty SM, Moawed FSM, Kandil EI, Abdel-Maksoud BE. Lactobacillus acidophilus ATCC 4356 Exopolysaccharides Suppresses Mediators of Inflammation through the Inhibition of TLR2/STAT-3/P38-MAPK Pathway in DEN-Induced Hepatocarcinogenesis in Rats. Nutr Cancer 2021;:1-11. [PMID: 34085875 DOI: 10.1080/01635581.2021.1934490] [Reference Citation Analysis]
23 Roudi R, D'Angelo A, Sirico M, Sobhani N. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. Int Immunopharmacol 2021;101:108322. [PMID: 34735916 DOI: 10.1016/j.intimp.2021.108322] [Reference Citation Analysis]
24 Chen D, Li X, Li H, Wang K, Tian X. Identification of Immune-Related Prognostic mRNA and lncRNA in Patients with Hepatocellular Carcinoma. J Oncol 2022;2022:5313149. [PMID: 35027925 DOI: 10.1155/2022/5313149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Wang Y, Yang L, Dong X, Yang X, Zhang X, Liu Z, Zhao X, Wen T. Overexpression of NNT-AS1 Activates TGF-β Signaling to Decrease Tumor CD4 Lymphocyte Infiltration in Hepatocellular Carcinoma. Biomed Res Int 2020;2020:8216541. [PMID: 33426064 DOI: 10.1155/2020/8216541] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Chen C, Gu Y, Wang R, Chai X, Jiang S, Wang S, Zhu Z, Chen X, Yuan Y. Comparative two-dimensional GPC3 overexpressing SK-Hep1 cell membrane chromatography /C18/ time-of-flight mass spectrometry for screening selective GPC3 inhibitor components from Scutellariae Radix. J Chromatogr B Analyt Technol Biomed Life Sci 2021;1163:122492. [PMID: 33418242 DOI: 10.1016/j.jchromb.2020.122492] [Reference Citation Analysis]
27 Wang T, Chen B, Meng T, Liu Z, Wu W. Identification and immunoprofiling of key prognostic genes in the tumor microenvironment of hepatocellular carcinoma. Bioengineered 2021;12:1555-75. [PMID: 33955820 DOI: 10.1080/21655979.2021.1918538] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Lu Z, Liu R, Wang Y, Jiao M, Li Z, Wang Z, Huang C, Shi G, Ke A, Wang L, Fu Y, Xia J, Wen H, Zhou J, Wang X, Ye D, Fan J, Chu Y, Cai J. Ten-eleven translocation-2 inactivation restrains IL-10-producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma. Hepatology 2022. [PMID: 35243663 DOI: 10.1002/hep.32442] [Reference Citation Analysis]
29 Üremiş N, Üremiş MM, Çiğremiş Y, Tosun E, Baysar A, Türköz Y. Cucurbitacin I exhibits anticancer efficacy through induction of apoptosis and modulation of JAK/STAT3, MAPK/ERK, and AKT/mTOR signaling pathways in HepG2 cell line. J Food Biochem 2022;:e14333. [PMID: 35866877 DOI: 10.1111/jfbc.14333] [Reference Citation Analysis]
30 Jia L, Gao Y, He Y, Hooper JD, Yang P. HBV induced hepatocellular carcinoma and related potential immunotherapy. Pharmacol Res. 2020;159:104992. [PMID: 32505833 DOI: 10.1016/j.phrs.2020.104992] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
31 You J, Gong Y, Wu Y, Jin L, Chi Q, Sun D. WGCNA, LASSO and SVM Algorithm Revealed RAC1 Correlated M0 Macrophage and the Risk Score to Predict the Survival of Hepatocellular Carcinoma Patients. Front Genet 2022;12:730920. [DOI: 10.3389/fgene.2021.730920] [Reference Citation Analysis]
32 Ma D, Wang J, Liu L, Chen M, Wang Z. Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study. BMC Cancer 2020;20:936. [PMID: 32993568 DOI: 10.1186/s12885-020-07447-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
33 Li X, Xu J, Gu X, Chen L, Wu Q, Li H, Bai H, Yang J, Qian J. Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma. Front Immunol 2021;12:740790. [PMID: 34733279 DOI: 10.3389/fimmu.2021.740790] [Reference Citation Analysis]
34 Liang H, Xu M, Xiong Z, Hu K, Yang J, Cao M, Zhong Z, Yao Z, Deng M, Liu B. Identification of miRNAs as diagnostic and prognostic markers in hepatocellular carcinoma. Aging (Albany NY) 2021;13:6115-33. [PMID: 33617479 DOI: 10.18632/aging.202606] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]